These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 23280281)

  • 21. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
    Ziakas PD; Kourbeti IS; Mylonakis E
    Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weekly fluconazole for preventing mucosal candidiasis in HIV infection.
    Baily G
    Ann Intern Med; 1997 Dec; 127(12):1131. PubMed ID: 9412323
    [No Abstract]   [Full Text] [Related]  

  • 23. [Flucoric--reliability in the treatment of fungal infections].
    Pavlova E; Ivanov S; Batashki I
    Akush Ginekol (Sofiia); 2008; 47 Suppl 1():10-1. PubMed ID: 18935849
    [No Abstract]   [Full Text] [Related]  

  • 24. Oral fluconazole 150 mg single dose versus intra-vaginal clotrimazole treatment of acute vulvovaginal candidiasis.
    Sekhavat L; Tabatabaii A; Tezerjani FZ
    J Infect Public Health; 2011 Sep; 4(4):195-9. PubMed ID: 22000847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vulvovaginal candidiasis from non-albicans species: retrospective study of recurrence rate after fluconazole therapy.
    Ventolini G; Baggish MS; Walsh PM
    J Reprod Med; 2006 Jun; 51(6):475-8. PubMed ID: 16846086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality of life in patients with chronic vulvovaginal candidiasis: A before and after study on the impact of oral fluconazole therapy.
    Nguyen Y; Lee A; Fischer G
    Australas J Dermatol; 2017 Nov; 58(4):e176-e181. PubMed ID: 27170259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis.
    Ray D; Goswami R; Banerjee U; Dadhwal V; Goswami D; Mandal P; Sreenivas V; Kochupillai N
    Diabetes Care; 2007 Feb; 30(2):312-7. PubMed ID: 17259500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated nitric oxide in recurrent vulvovaginal candidiasis - association with clinical findings.
    Alvendal C; Ehrström S; Brauner A; Lundberg JO; Bohm-Starke N
    Acta Obstet Gynecol Scand; 2017 Mar; 96(3):295-301. PubMed ID: 28052314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Term Outcomes of Women With Recurrent Vulvovaginal Candidiasis After a Course of Maintenance Antifungal Therapy.
    Crouss T; Sobel JD; Smith K; Nyirjesy P
    J Low Genit Tract Dis; 2018 Oct; 22(4):382-386. PubMed ID: 29975334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined systemic (fluconazole) and topical (metronidazole + clotrimazole) therapy for a new approach to the treatment and prophylaxis of recurrent candidiasis.
    Genovese C; Cianci A; Corsello S; Ettore G; Mattana P; Tempera G
    Minerva Ginecol; 2019 Aug; 71(4):321-328. PubMed ID: 31106557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Combined single-day treatment in acute vulvovaginal candidosis].
    Kovachev S; Nacheva A; Vacheva-Dobrevska R; Vasilev N
    Akush Ginekol (Sofiia); 2009; 48(6):18-23. PubMed ID: 20225492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is there a role for fluconazole in the treatment of vulvovaginal candidiasis?
    Patel HS; Peters MD; Smith CL
    Ann Pharmacother; 1992 Mar; 26(3):350-3. PubMed ID: 1554957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic vulvovaginal candidiasis.
    Kuebrich CT
    N Engl J Med; 2004 Dec; 351(24):2554-6; author reply 2554-6. PubMed ID: 15590964
    [No Abstract]   [Full Text] [Related]  

  • 34. Interplay of the microbiome and antifungal therapy in recurrent vulvovaginal candidiasis (RVVC): A narrative review.
    Bradfield Strydom M; Khan S; Walpola RL; Ware RS; Tiralongo E
    J Med Microbiol; 2023 May; 72(5):. PubMed ID: 37171871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vulvovaginitis: screening for and management of trichomoniasis, vulvovaginal candidiasis, and bacterial vaginosis.
    van Schalkwyk J; Yudin MH;
    J Obstet Gynaecol Can; 2015 Mar; 37(3):266-274. PubMed ID: 26001874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis.
    Garvey EP; Hoekstra WJ; Schotzinger RJ; Sobel JD; Lilly EA; Fidel PL
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5567-73. PubMed ID: 26124165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "Efficacy and safety of oteseconazole in recurrent vulvovaginal candidiasis (RVVC) - A systematic review and meta-analysis".
    Siddiqui T; Kumar KA; Iqbal A; Doultani PR; Ashraf T; Eqbal F; Siddiqui SI
    Heliyon; 2023 Nov; 9(11):e20495. PubMed ID: 37920530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Genital candidiasis].
    Ono F; Yasumoto S
    Nihon Rinsho; 2009 Jan; 67(1):157-61. PubMed ID: 19177766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative study on the effectiveness of antifungal agents in different regimens against vaginal candidiasis.
    Mikamo H; Kawazoe K; Sato Y; Hayasaki Y; Tamaya T
    Chemotherapy; 1998; 44(5):364-8. PubMed ID: 9732153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biofilms Formed by Isolates from Recurrent Vulvovaginal Candidiasis Patients Are Heterogeneous and Insensitive to Fluconazole.
    Sherry L; Kean R; McKloud E; O'Donnell LE; Metcalfe R; Jones BL; Ramage G
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.